ALL YOU NEED TO KNOW ABOUT NASAL VACCINE

A nasal vaccine for COVID-19 is inserted through the nose to restrict the virus's spread in the mucosal region. This prevents the virus from triggering an immune response from cells and molecules in this region. These vaccinations do not require special training and the procedure is painless and needle-free. Thus, nasal vaccines overcome vaccine hesitancy and remove needle-associated risks.

Nasal vaccines target the mucosal lining and activate the immune system right where the virus enters the body, which is primarily through the nose and mouth. By producing and neutralising IgG, mucosal IgA, and T-cell responses, these vaccines promote immunity. Nasal vaccines, also known as sterling immunity, have been found to significantly reduce virus transmission, even in asymptomatic and mild cases.

Some side effects of nasal vaccines are headache, fever, runny nose, and sneezing. These vaccines are not being given to people allergic to any of its components, who had a severe allergic reaction to it in the past and who have acute infection or fever.

Nasal vaccines have been approved for people of the age group of 18 years and above as booster doses. These vaccines are given as 0.5ml doses (8 drops - 4 drops in each nostril) after 4 weeks of intervals.

Nasal vaccines as a fourth dose are not currently accepted by COWIN. As well as, regular immunization, and administering them at short intervals can cause ‘antigen skin’ which will limit the body’s ability to respond to the vaccines. This is also the reason why only people who have taken 2 doses of covid-19 vaccine are being given the option of nasal vaccines as a booster dose.

However, INCOVACC is available as an option on the COWIN platform. The doses will be rolled out in the fourth week of January 2023. These vaccines will be available near your hospitals and private medical centres.